Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration
30. Juni 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn. and MANCHESTER, United Kingdom, June 30, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) (“Bioasis”) and Oxyrane UK Ltd. (“Oxyrane”) are pleased to...
Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners
29. Juni 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., June 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
25. Juni 2021 17:33 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., June 25, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million
22. Juni 2021 20:10 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Publication Validating its xB³ ™ Platform Technology for CNS Therapeutics
03. Juni 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration
31. März 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology
29. März 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing
24. März 2021 17:15 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Technologies Inc. Announces Warrant Extension and Repricing
22. März 2021 18:30 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company...
Bioasis to Attend and Present at Upcoming Investor and Industry Conferences
08. März 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 08, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...